- 501 Orchard Road, #04-08 Wheelock Place, Singapore 238880
- (65) 6235 4429
- hello@vidaskinclinic.com
- (65) 9830 0597
Many people use the words “melasma” and “pigmentation” as though they mean the same thing, but they are not interchangeable. Pigmentation is a broad umbrella term for changes in skin colour, while melasma is a specific and often chronic pigment disorder with a more complex pattern of triggers.
Understanding the difference is crucial because treatment strategies, maintenance, and expectations can vary significantly. A brown spot caused by sun damage is not managed in the same way as melasma, and treating both as though they are identical can lead to frustration and recurrence.
Pigmentation refers to the colour of the skin, which is largely determined by melanin. When people talk about “pigmentation” in a cosmetic or dermatological sense, they usually mean areas of excess pigment or uneven darkening, also known as hyperpigmentation.
Hyperpigmentation can appear as spots, patches, or uneven tone, and it may be triggered by various processes, including UV exposure, inflammation, hormones, heat, and skin injury. This is why a proper diagnosis matters before treatment begins.
Melanin is produced by specialised cells called melanocytes. These cells sit in the skin and manufacture pigment, which is then transferred to surrounding skin cells to help protect the skin from ultraviolet radiation.
This process is normal and protective, but it can become overactive. When melanocytes are stimulated excessively or repeatedly, the skin can produce too much pigment in certain areas, resulting in visible darkening.
Hyperpigmentation is not one single condition. Common forms include post-inflammatory hyperpigmentation after acne or irritation, solar lentigines or sun spots from chronic UV exposure, and melasma, which has a distinct hormonal and genetic component.
Because these conditions can look similar to a patient but behave differently biologically, they often respond differently to the same treatment. That is one of the main reasons why self-diagnosing pigment problems can be misleading.
Pigment changes often develop gradually because the skin responds cumulatively to repeated triggers. Sunlight, visible light, inflammation, friction, heat, and hormonal fluctuations can all keep pigment-producing pathways switched on over time.
As these signals accumulate, the skin may start to darken in recurring areas. In some people, the pigment sits more superficially, while in others it can involve deeper layers or mixed patterns, which affects how easy it is to treat.
Melasma is a specific acquired pigment condition that usually appears as symmetrical brown, tan, or grey-brown patches on the face. It commonly affects the cheeks, forehead, upper lip and chin, and unlike many simple sun spots, it often reflects a combination of internal and external triggers.
This is what makes melasma more challenging. It is not simply a mark left behind by the sun; it is a disorder of pigment regulation that is often influenced by hormones, genetics, chronic light exposure, and inflammation.
Melasma develops when pigment pathways become dysregulated, and melanin accumulates in the epidermis, dermis, or both. This helps explain why some cases are more superficial and easier to improve, while others are more persistent or relapse more easily.
Modern understanding of melasma also goes beyond melanocytes alone. Vascular factors, inflammation, barrier dysfunction, and light-driven stimulation may all contribute to why melasma is so stubborn in some patients.
Hormones play a major role in melasma for many patients. Pregnancy, birth control, hormone replacement therapy, and other hormone shifts are recognised associations, and family history also increases susceptibility.
Not everyone exposed to these triggers develops melasma, which suggests an underlying genetic predisposition in susceptible individuals. This is one reason melasma often behaves differently from straightforward sun-induced pigmentation.
Melasma is often described as chronic and recurrent because the pigment tendency can remain active even after the visible patches have lightened. The skin may look better after treatment, but the biological drive toward pigment overproduction can still be present.
That is why maintenance is so important. Without ongoing sun protection, trigger management, and consistent pigment control, recurrence is common even after good initial improvement.
Common melasma triggers include UV exposure, visible light, heat, hormonal shifts, inflammation, and certain medications. Stress and barrier disruption may also aggravate the condition in some individuals.
The key point is that melasma usually has multiple triggers acting together rather than just one isolated cause. This is why treatment often needs to address more than just the visible pigment itself.
Sun spots and melasma are both forms of hyperpigmentation, but they are not the same condition. Sun spots are usually more directly related to cumulative UV exposure, while melasma often reflects a broader network of triggers involving hormones, genetics, and light sensitivity.
This distinction matters because visible similarity does not always mean biological similarity. Two brown marks may look alike to the patient but require very different treatment logic.
Sun spots, also known as solar lentigines, usually develop after long-term ultraviolet exposure, which causes localised overproduction of melanin. They are common in areas that receive repeated sun exposure over the years.
Because the trigger is often more straightforward, sun spots can sometimes respond more predictably to pigment-targeting procedures when compared with melasma. That does not mean they are always easy, but their biology is often less complex.
Melasma is more complicated because ultraviolet exposure is only one part of the story. Visible light, heat, hormones, vascular activity, and underlying susceptibility may all contribute to recurrent pigment activation.
This multi-trigger behaviour helps explain why melasma can worsen even when a patient feels they are “not in the sun much”. It also explains why a plan focused on one trigger alone may not be enough.
Sun spots are often more discrete and individualised, appearing as separated brown spots in sun-exposed areas. Melasma more commonly appears as broader, patchier and often symmetrical areas of discolouration, especially across the cheeks, forehead, upper lip and chin.
These visual clues are useful, but they are not the whole story. Clinical assessment is still important because mixed pigment patterns can occur, and some patients have melasma plus other forms of pigmentation at the same time.
Treatment response varies because not all pigmentation behaves the same way under topical agents, peels, or lasers. A sun spot may fade well when the pigment is targeted directly, whereas melasma may improve and then flare again if the upstream triggers remain active.
This is why patients sometimes feel confused when one pigment mark clears and another returns. The treatment was not necessarily wrong; the underlying biology may simply be different.
Topical treatment often forms the foundation of pigment management, especially in melasma. These products are used not only to fade existing pigment, but also to suppress ongoing melanin production and reduce the likelihood of relapse.
The exact routine varies by skin type, sensitivity, and diagnosis. Some patients need stronger prescription combinations, while others need a gentler maintenance-focused plan that protects the barrier while controlling pigment activity.
A patient with resilient skin may tolerate a more active maintenance programme than a patient with reactive, easily sensitised skin. Likewise, someone with recurrent melasma may need longer-term suppression than someone with simpler post-inflammatory pigmentation.
For this reason, there is no universal post-laser brightening routine that suits everyone. A medically guided maintenance plan is usually safer than self-layering multiple lightening products after a procedure.
Tyrosinase is a key enzyme involved in melanin production, which is why tyrosinase inhibitors are central to many pigment protocols. Commonly used agents include hydroquinone, arbutin, azelaic acid, kojic acid, ascorbic acid, and topical tranexamic acid, depending on the patient and the treatment plan.
These ingredients help reduce pigment production upstream rather than only treating what is already visible on the surface. This makes them especially relevant in melasma, where ongoing suppression is often needed.
Antioxidants are commonly used to help reduce oxidative stress and support skin defence against environmental triggers. They are not a complete solution on their own, but they can support broader pigment management and complement sun protection.
Ingredients such as vitamin C may be used as part of an overall maintenance programme. Their role is usually supportive rather than standalone, especially in established melasma.
Barrier repair matters because irritated or inflamed skin is more likely to pigment poorly and respond unpredictably. Ingredients that support the skin barrier can help reduce reactivity, improve tolerance to active treatments, and support long-term maintenance.
This is particularly important in patients who have already overused strong acids, peels or bleaching agents. A damaged barrier can make pigment harder to stabilise, not easier.
Pigment control is usually not a one-time event. Melasma in particular often improves only with steady, repeated suppression of the pathways that drive pigment formation.
This is why consistency matters more than intensity alone. Good maintenance with appropriate topical care, sun protection, and trigger management often determines how durable the result will be.
A multi-modal approach is often preferred because pigmentation and melasma are rarely caused by just one factor. If the problem involves melanin, inflammation, light exposure, vascular influence, and barrier dysfunction, then targeting only one pathway may give incomplete results.
This is especially true for melasma, where recurrence is common and upstream control matters. A broader strategy often produces more stable improvement and better long-term control.
Different treatment tools work on different parts of the problem. Some reduce pigment formation, some accelerate clearance, some control inflammation, and some address visible pigment already deposited in the skin.
By addressing multiple causes, treatment becomes more rational and often more durable. This is one reason why melasma management has shifted toward layered rather than single-solution plans.
Topicals are often combined with in-clinic treatments such as depigmentation protocols, chemical peels, or carefully selected laser programmes. At VIDASKIN, lasers are used as part of a personalised programme rather than a one-size-fits-all approach.
This matters because different pigment patterns respond differently to energy-based treatment. In some cases, topical suppression must be established first before procedural work is introduced.
No two pigment journeys are identical. Skin type, sensitivity, trigger profile, chronicity, treatment history, and lifestyle all affect how aggressive or conservative the plan should be.
A personalised approach helps reduce unnecessary irritation and improves the odds of long-term control. This is especially important in melasma, where over-treatment can sometimes worsen the problem.
If you are unsure whether you are dealing with melasma, sun spots, or another form of pigmentation, the most useful next step is proper assessment rather than guessing. Similar-looking brown marks may need very different treatment plans depending on what is driving them.
At VIDASKIN, treatment plans are tailored to the biology of the pigment problem, the sensitivity of the skin, and the long-term goal of control rather than short-lived improvement alone. The aim is not just to fade pigment temporarily, but to create a plan that your skin can maintain over time.
No. Pigmentation is a broad term, while melasma is a specific pigment disorder with hormonal, genetic, and light-related influences.
Sun spots are usually more directly linked to cumulative UV exposure, while melasma often has multiple triggers, including hormones, visible light, and genetic susceptibility.
Melasma is often chronic and recurrent because the tendency toward pigment overproduction can remain active even after the visible patches improve.
Common options include tyrosinase inhibitors such as hydroquinone, azelaic acid, arbutin, kojic acid, ascorbic acid, and topical tranexamic acid, depending on the skin and treatment plan.
Because melasma is usually driven by more than one pathway, combining topical care, sun protection, and selected in-clinic treatments often provides better long-term control than relying on a single treatment alone.
